Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019066442) LACTOFERRIN-BASED GENE CARRIER FOR TYPE 2 DIABETES TREATMENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/066442 International Application No.: PCT/KR2018/011336
Publication Date: 04.04.2019 International Filing Date: 21.09.2018
IPC:
A61K 48/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants:
한양대학교 산학협력단 INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY [KR/KR]; 서울시 성동구 왕십리로 222 한양대학교 Hanyang Univ., 222, Wangsimni-ro, Seongdong-gu, Seoul 04763, KR
Inventors:
이동윤 LEE, Dong Yun; KR
이창우 LEE, Chang Woo; KR
이승아 LEE, Seungah; KR
Agent:
특허법인 다나 DANA PATENT LAW FIRM; 서울시 강남구 역삼로 3길 11 광성빌딩 신관 5층 5th Floor, New Wing, Gwangsung Bldg., 11, Yeoksam-ro 3-gil, Gangnam-gu, Seoul 06242, KR
Priority Data:
10-2017-012493527.09.2017KR
10-2018-010720407.09.2018KR
Title (EN) LACTOFERRIN-BASED GENE CARRIER FOR TYPE 2 DIABETES TREATMENT
(FR) VECTEUR GÉNÉTIQUE À BASE DE LACTOFERRINE POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2
(KO) 제2형 당뇨병 치료를 위한 락토페린 기반의 유전자 전달체
Abstract:
(EN) The present invention relates to a gene delivery complex comprising: a biocompatible polymer backbone; and pegylated lactoferrin connected to the biocompatible polymer backbone by means of a covalent bond. The gene delivery complex is orally administered into an individual, can be absorbed in vivo by means of a lactoferrin receptor, and enables the in vivo delivery of a target gene and the expression thereof.
(FR) La présente invention concerne un complexe d'insertion de gènes comprenant : un squelette polymère biocompatible; et de la lactoferrine pégylée reliée au squelette polymère biocompatible par l'intermédiaire d'une liaison covalente. Le complexe d'insertion de gènes est administré par voie orale à un sujet, peut être absorbé in vivo par l'intermédiaire d'un récepteur de lactoferrine et permet l'insertion in vivo d'un gène cible et son expression.
(KO) 본 발명은 생체적합성 고분자 백본 및 상기 생체적합성 고분자 백본에 공유결합으로 연결된 페길화된 락토페린(pegylated lactoferrin)을 포함하는 유전자 전달용 복합체에 관한 것으로, 상기 유전자 전달용 복합체는 개체 내에 경구로 투여되어 락토페린 수용체를 통하여 체내로 흡수될 수 있으며, 표적 유전자를 생체 내로 전달하여 발현시킬 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)